Cyfuse Biomedical K.K Management

Management criteria checks 2/4

Cyfuse Biomedical K.K's CEO is Shizuka Akieda, appointed in Mar 2018, has a tenure of 8.5 years. directly owns 5.53% of the company’s shares, worth ¥447.54M. The average tenure of the management team and the board of directors is 7 years and 5 years respectively.

Key information

Shizuka Akieda

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7yrs
CEO ownership5.5%
Management average tenure7yrs
Board average tenure5yrs

Recent management updates

Recent updates

Is Cyfuse Biomedical K.K (TSE:4892) Using Too Much Debt?

Dec 04
Is Cyfuse Biomedical K.K (TSE:4892) Using Too Much Debt?

Is Cyfuse Biomedical K.K (TSE:4892) Weighed On By Its Debt Load?

Jul 16
Is Cyfuse Biomedical K.K (TSE:4892) Weighed On By Its Debt Load?

Is Cyfuse Biomedical K.K (TSE:4892) A Risky Investment?

Mar 01
Is Cyfuse Biomedical K.K (TSE:4892) A Risky Investment?

CEO

Shizuka Akieda (48 yo)

7yrs

Tenure

Ms. Shizuka Akieda serves as President at Cyfuse Biomedical K.K. since March 2018 and its Director since September 2016. She served as researcher in genomics and regenerative medicine field at Kyushu Unive...


Leadership Team

NamePositionTenureCompensationOwnership
Shizuka Akieda
President & Representative Director7yrsno data5.53%
¥ 447.5m
Koichi Nakayama
Co-Founderno datano datano data
Masahiro Sanjo
CFO, Director of Business Administration Department & Director9.3yrsno data4.08%
¥ 330.3m
Norihiko Tokunaga
GM of System Development Department & Director4yrsno data0.19%
¥ 15.4m

7.0yrs

Average Tenure

48yo

Average Age

Experienced Management: 4892's management team is seasoned and experienced (7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Shizuka Akieda
President & Representative Director8.5yrsno data5.53%
¥ 447.5m
Masahiro Sanjo
CFO, Director of Business Administration Department & Director7yrsno data4.08%
¥ 330.3m
Norihiko Tokunaga
GM of System Development Department & Director4yrsno data0.19%
¥ 15.4m
Yasuhiro Yoshioka
Independent Outside Director6yrsno datano data
Yoichi Oda
Full-Time Audit & Supervisory Board Member6.8yrsno datano data
Takuo Hirose
Outside Audit & Supervisory Board Member4yrsno datano data
Kazuya Oda
Outside Audit & Supervisory Board Member4yrsno datano data
Kunihiko Suzuki
Independent Outside Director4yrsno datano data

5.0yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 4892's board of directors are considered experienced (5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 12:36
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cyfuse Biomedical K.K. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.